公开(公告)号：US20210349097A1

公开(公告)日：2021-11-11

申请号：US17282193

申请日：2019-10-02

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yasuhiro Funahashi ,  Yukinori Minoshima ,  Michio Kanekiyo ,  Masahiro Matsuki ,  Yusuke Adachi ,  Kotaro Kodama

IPC: G01N33/574 ,  A61P35/04 ,  A61K31/47 ,  A61K31/436 ,  C12Q1/6886

Abstract: Biomarkers are provided that predict whether a human subject having a renal cell carcinoma is responsive to a combination therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate) and everolimus. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a renal cell carcinoma.

公开(公告)号：US20210333281A1

公开(公告)日：2021-10-28

申请号：US17282218

申请日：2019-10-02

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yasuhiro Funahashi ,  Yukinori Minoshima ,  Michio Kanekiyo ,  Saori Miyano ,  Taisuke Hoshi

IPC: G01N33/574 ,  A61K31/47 ,  A61P35/00 ,  C12Q1/6886

Abstract: Biomarkers are provided that predict whether a subject having a hepatocellular carcinoma is responsive to a therapy comprising soratenib or a pharmaceutically acceptable salt thereof. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a hepatocellular carcinoma.

公开(公告)号：US20140148483A1

公开(公告)日：2014-05-29

申请号：US14117276

申请日：2012-05-16

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Taro Semba ,  Yusuke Narita ,  Yukinori Minoshima ,  Atsumi Yamaguchi ,  Yusuke Adachi ,  Kazuhiko Yamada ,  Junji Matsui ,  Tadashi Kadowaki ,  Kentaro Takahashi ,  Yasuhiro Funahashi

IPC: C12Q1/68 ,  A61K31/47

CPC classification number: C12Q1/6886 ,  A61K31/4025 ,  A61K31/404 ,  A61K31/47 ,  A61K31/517 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/574 ,  G01N33/5748 ,  G01N33/57488 ,  G01N33/57496 ,  G01N2333/515 ,  G01N2333/82 ,  G01N2333/916 ,  G01N2800/52

Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.

Abstract translation: 本发明的目的是提供一种用于预测患有肿瘤的受试者中血管生成抑制剂的有效性的方法。 提供了一种方法，其包括测试来自受试者的肿瘤组织样品中是否存在B-Raf和PTEN的突变或丧失的表达的存在或不存在的步骤。 通过使用B-Raf和PTEN的表达的存在或不存在或突变或丧失作为指标，该方法能够预测血管生成抑制剂的抗肿瘤效力，而不向受试者施用血管生成抑制剂。

公开(公告)号：US20230212679A1

公开(公告)日：2023-07-06

申请号：US17692698

申请日：2022-03-11

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Taro Semba ,  Yusuke Narita ,  Yukinori Minoshima ,  Atsumi Yamaguchi ,  Yusuke Adachi ,  Kazuhiko Yamada ,  Junji Matsui ,  Tadashi Kadowaki ,  Kentaro Takahashi ,  Yasuhiro Funahashi

IPC: C12Q1/6886 ,  A61K31/47 ,  G01N33/574 ,  A61K31/517 ,  A61K31/404 ,  A61K31/4025

CPC classification number: C12Q1/6886 ,  A61K31/47 ,  A61K31/404 ,  A61K31/517 ,  A61K31/4025 ,  G01N33/574 ,  G01N33/5748 ,  G01N33/57488 ,  G01N33/57496 ,  C12Q2600/16 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2333/82 ,  G01N2333/515 ,  G01N2333/916 ,  G01N2800/52

Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.

公开(公告)号：US20170191137A1

公开(公告)日：2017-07-06

申请号：US15460629

申请日：2017-03-16

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Taro Semba ,  Yusuke Narita ,  Yukinori Minoshima ,  Atsumi Yamaguchi ,  Yusuke Adachi ,  Kazuhiko Yamada ,  Junji Matsui ,  Tadashi Kadowaki ,  Kentaro Takahashi ,  Yasuhiro Funahashi

IPC: C12Q1/68 ,  G01N33/574 ,  A61K31/47

CPC classification number: C12Q1/6886 ,  A61K31/4025 ,  A61K31/404 ,  A61K31/47 ,  A61K31/517 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/574 ,  G01N33/5748 ,  G01N33/57488 ,  G01N33/57496 ,  G01N2333/515 ,  G01N2333/82 ,  G01N2333/916 ,  G01N2800/52

Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.